Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
Capone M, Giannarelli D, Mallardo D, Madonna G, Festino L, Grimaldi AM, Vanella V, Simeone E, Paone M, Palmieri G, Cavalcanti E, Caracò C, Ascierto PA. Capone M, et al. Among authors: cavalcanti e. J Immunother Cancer. 2018 Jul 16;6(1):74. doi: 10.1186/s40425-018-0383-1. J Immunother Cancer. 2018. PMID: 30012216 Free PMC article.
Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma.
Daponte A, Signoriello S, Maiorino L, Massidda B, Simeone E, Grimaldi AM, Caracò C, Palmieri G, Cossu A, Botti G, Petrillo A, Lastoria S, Cavalcanti E, Aprea P, Mozzillo N, Gallo C, Comella G, Ascierto PA; Southern Italy Cooperative Oncology Group (SICOG). Daponte A, et al. Among authors: cavalcanti e. J Transl Med. 2013 Feb 13;11:38. doi: 10.1186/1479-5876-11-38. J Transl Med. 2013. PMID: 23402397 Free PMC article. Clinical Trial.
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma.
Simeone E, Gentilcore G, Giannarelli D, Grimaldi AM, Caracò C, Curvietto M, Esposito A, Paone M, Palla M, Cavalcanti E, Sandomenico F, Petrillo A, Botti G, Fulciniti F, Palmieri G, Queirolo P, Marchetti P, Ferraresi V, Rinaldi G, Pistillo MP, Ciliberto G, Mozzillo N, Ascierto PA. Simeone E, et al. Among authors: cavalcanti e. Cancer Immunol Immunother. 2014 Jul;63(7):675-83. doi: 10.1007/s00262-014-1545-8. Epub 2014 Apr 3. Cancer Immunol Immunother. 2014. PMID: 24695951 Free PMC article.
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment.
Caputo E, Miceli R, Motti ML, Taté R, Fratangelo F, Botti G, Mozzillo N, Carriero MV, Cavalcanti E, Palmieri G, Ciliberto G, Pirozzi G, Ascierto PA. Caputo E, et al. Among authors: cavalcanti e. J Transl Med. 2014 Jul 31;12:216. doi: 10.1186/s12967-014-0216-z. J Transl Med. 2014. PMID: 25074438 Free PMC article.
Ran signaling in melanoma: implications for the development of alternative therapeutic strategies.
Caputo E, Wang E, Valentino A, Crispi S, De Giorgi V, Fico A, Ficili B, Capone M, Anniciello A, Cavalcanti E, Botti G, Mozzillo N, Ascierto PA, Marincola FM, Travali S. Caputo E, et al. Among authors: cavalcanti e. Cancer Lett. 2015 Feb 1;357(1):286-296. doi: 10.1016/j.canlet.2014.11.033. Epub 2014 Nov 20. Cancer Lett. 2015. PMID: 25444926 Free PMC article.
Phenotype characterization of human melanoma cells resistant to dabrafenib.
Cordaro FG, De Presbiteris AL, Camerlingo R, Mozzillo N, Pirozzi G, Cavalcanti E, Manca A, Palmieri G, Cossu A, Ciliberto G, Ascierto PA, Travali S, Patriarca EJ, Caputo E. Cordaro FG, et al. Among authors: cavalcanti e. Oncol Rep. 2017 Nov;38(5):2741-2751. doi: 10.3892/or.2017.5963. Epub 2017 Sep 18. Oncol Rep. 2017. PMID: 29048639 Free PMC article.
Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodology.
Pascarella G, Capasso A, Nardone A, Triassi M, Pignata S, Arenare L, Ascierto P, Curvietto M, Maiolino P, D'Aniello R, Montanino A, Laudato F, De Feo G, Botti G, Perrone F, Petrillo A, Cavalcanti E, Lastoria S, Maurea N, Morabito A. Pascarella G, et al. Among authors: cavalcanti e. PLoS One. 2019 Jan 8;14(1):e0210330. doi: 10.1371/journal.pone.0210330. eCollection 2019. PLoS One. 2019. PMID: 30620767 Free PMC article.
Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients.
Capone M, Fratangelo F, Giannarelli D, Sorrentino C, Turiello R, Zanotta S, Galati D, Madonna G, Tuffanelli M, Scarpato L, Grimaldi AM, Esposito A, Azzaro R, Pinto A, Cavalcanti E, Pinto A, Morello S, Ascierto PA. Capone M, et al. Among authors: cavalcanti e. J Transl Med. 2020 Mar 11;18(1):121. doi: 10.1186/s12967-020-02285-0. J Transl Med. 2020. PMID: 32160899 Free PMC article.
The clinical and translational research activities at the INT - IRCCS "Fondazione Pascale" cancer center (Naples, Italy) during the COVID-19 pandemic.
Buonaguro FM, Botti G, Ascierto PA, Pignata S, Ionna F, Delrio P, Petrillo A, Cavalcanti E, Di Bonito M, Perdonà S, De Laurentiis M, Fiore F, Palaia R, Izzo F, D'Auria S, Rossi V, Menegozzo S, Piccirillo M, Celentano E, Cuomo A, Normanno N, Tornesello ML, Saviano R, Barberio D, Buonaguro L, Giannoni G, Muto P, Miscio L, Bianchi AAM; and the INT-Pascale COVID-19 Crisis Unit. Buonaguro FM, et al. Among authors: cavalcanti e. Infect Agent Cancer. 2020 Nov 23;15(1):69. doi: 10.1186/s13027-020-00330-7. Infect Agent Cancer. 2020. PMID: 33292365 Free PMC article.
182 results